Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020;383:2628–2638.

• PubMed
Beck DB, Ferrada MA, Sikora KA, Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020;383:2628–2638.)| false
• Search Google Scholar
• Export Citation

National Cancer Institute. SEER cancer statistics review 1975–2016: myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD), and chronic myelomonocytic leukemia (CMML). Accessed January 8, 2020. Available at: https://seer.cancer.gov/csr/1975_2016/browse_csr.php?sectionSEL=30&pageSEL=sect_30_intro.01

• PubMed
National Cancer Institute. SEER cancer statistics review 1975–2016: myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD), and chronic myelomonocytic leukemia (CMML). Accessed January 8, 2020. Available at: https://seer.cancer.gov/csr/1975_2016/browse_csr.php?sectionSEL=30&pageSEL=sect_30_intro.01)| false
• Search Google Scholar
• Export Citation

Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev 2019;34:1–15.

• PubMed
Zeidan AM, Shallis RM, Wang R, Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev 2019;34:1–15.)| false
• Search Google Scholar
• Export Citation

Greenberg P. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, eds. Hematology: Basic Principles and Practice, 3rd ed. Churchill Livingstone; 2000:1106–1129.

• PubMed
Greenberg P. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, eds. Hematology: Basic Principles and Practice, 3rd ed. Churchill Livingstone; 2000:1106–1129.)| false
• Search Google Scholar
• Export Citation

Sasaki K, Jabbour E, Montalban-Bravo G, et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evid 2022;1:EVIDoa2200034.

• PubMed
Sasaki K, Jabbour E, Montalban-Bravo G, Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evid 2022;1:EVIDoa2200034.)| false
• Search Google Scholar
• Export Citation

Platzbecker U, Wong RS, Verma A, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol 2015;2:e417–426.

• PubMed
Platzbecker U, Wong RS, Verma A, Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol 2015;2:e417–426.)| false
• Search Google Scholar
• Export Citation

Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol 2017;4:e127–136.

• PubMed
Oliva EN, Alati C, Santini V, Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol 2017;4:e127–136.)| false
• Search Google Scholar
• Export Citation

Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/ intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014;120:1838–1846.

• PubMed
Giagounidis A, Mufti GJ, Fenaux P, Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/ intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014;120:1838–1846.)| false
• Search Google Scholar
• Export Citation

Platzbecker U, Santini V, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;403:249–260.

• PubMed
Platzbecker U, Santini V, Fenaux P, Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;403:249–260.)| false
• Search Google Scholar
• Export Citation

Della Porta MG, Garcia-Manero G, Santini V, et al. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion- dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol 2024;11:e646–658.

• PubMed
Della Porta MG, Garcia-Manero G, Santini V, Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion- dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol 2024;11:e646–658.)| false
• Search Google Scholar
• Export Citation

Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 2023;402:373–385.

• PubMed
Platzbecker U, Della Porta MG, Santini V, Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 2023;402:373–385.)| false
• Search Google Scholar
• Export Citation

Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527–536.

• PubMed
Moyo V, Lefebvre P, Duh MS, Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527–536.)| false
• Search Google Scholar
• Export Citation

Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382:140–151.

• PubMed
Fenaux P, Platzbecker U, Mufti GJ, Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382:140–151.)| false
• Search Google Scholar
• Export Citation

Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67–71.

• PubMed
Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67–71.)| false
• Search Google Scholar
• Export Citation

Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076–4081.

• PubMed
Negrin RS, Stein R, Doherty K, Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076–4081.)| false
• Search Google Scholar
• Export Citation

Greenberg P. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. J Pediatr Hematol Oncol 1997;4:231–238.

• PubMed
Greenberg P. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. J Pediatr Hematol Oncol 1997;4:231–238.)| false
• Search Google Scholar
• Export Citation

Garcia-Manero G, McCloskey J, Griffiths EA, et al. Oral decitabine- cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol 2024;11:e15–26.

• PubMed
Garcia-Manero G, McCloskey J, Griffiths EA, Oral decitabine- cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol 2024;11:e15–26.)| false
• Search Google Scholar
• Export Citation

Garcia JS, Platzbecker U, Odenike O, et al. Efficacy and safety of venetoclax in combination with azacitidine for the treatment of patients with treatment-naive, higher-risk myelodysplastic syndromes. Blood 2023;142(Suppl 1):319.

• PubMed
Garcia JS, Platzbecker U, Odenike O, Efficacy and safety of venetoclax in combination with azacitidine for the treatment of patients with treatment-naive, higher-risk myelodysplastic syndromes. Blood 2023;142(Suppl 1):319.)| false
• Search Google Scholar
• Export Citation

Zeidan AM, Pollyea DA, Garcia JS, et al. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. Blood 2019;134(Suppl 1):565.

• PubMed
Zeidan AM, Pollyea DA, Garcia JS, A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. Blood 2019;134(Suppl 1):565.)| false
• Search Google Scholar
• Export Citation

Bazinet A, Darbaniyan F, Jabbour E, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study. Lancet Haematol 2022;9:e756–765.

• PubMed
Bazinet A, Darbaniyan F, Jabbour E, Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study. Lancet Haematol 2022;9:e756–765.)| false
• Search Google Scholar
• Export Citation

Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol 2023;98:272–281.

• PubMed
Zeidan AM, Borate U, Pollyea DA, A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol 2023;98:272–281.)| false
• Search Google Scholar
• Export Citation

Lachowiez CA, Loghavi S, Zeng Z, et al. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 2023;4:276–293.

• PubMed
Lachowiez CA, Loghavi S, Zeng Z, A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 2023;4:276–293.)| false
• Search Google Scholar
• Export Citation

Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95:1668–1674.

• PubMed
Thol F, Weissinger EM, Krauter J, IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95:1668–1674.)| false
• Search Google Scholar
• Export Citation

Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094–1096.

• PubMed
Kosmider O, Gelsi-Boyer V, Slama L, Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094–1096.)| false
• Search Google Scholar
• Export Citation

Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012;26:101–105.

• PubMed
Patnaik MM, Hanson CA, Hodnefield JM, Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012;26:101–105.)| false
• Search Google Scholar
• Export Citation

DiNardo CD, Roboz GJ, Watts JM, et al. Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv 2024;8:4209–4220.

• PubMed
DiNardo CD, Roboz GJ, Watts JM, Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv 2024;8:4209–4220.)| false
• Search Google Scholar
• Export Citation

Cortes J, Yang J, Lee S, et al. Olutasidenib alone or in combination with azacitidine induces durable complete remissions in patients with mIDH1 myelodysplastic syndromes/neoplasms (MDS). Blood 2023;142(Suppl 1):1872.

• PubMed
Cortes J, Yang J, Lee S, Olutasidenib alone or in combination with azacitidine induces durable complete remissions in patients with mIDH1 myelodysplastic syndromes/neoplasms (MDS). Blood 2023;142(Suppl 1):1872.)| false
• Search Google Scholar
• Export Citation

Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med 2022;386:1519–1531.

• PubMed
Montesinos P, Recher C, Vives S, Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med 2022;386:1519–1531.)| false
• Search Google Scholar
• Export Citation

Sebert M, Cluzeau T, Rauzy OB, et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM group. Blood 2021;138(Suppl 1):62.

• PubMed
Sebert M, Cluzeau T, Rauzy OB, Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM group. Blood 2021;138(Suppl 1):62.)| false
• Search Google Scholar
• Export Citation

Ades L, Dimicoli-Salazar S, Sebert M, et al. Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the Ideal phase 2 study by the GFM group. Blood 2021;138(Suppl 1):Abstract 63.

• PubMed
Ades L, Dimicoli-Salazar S, Sebert M, Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the Ideal phase 2 study by the GFM group. Blood 2021;138(Suppl 1):Abstract 63.)| false
• Search Google Scholar
• Export Citation

Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol 2021;39:3328–3339.

• PubMed
Nakamura R, Saber W, Martens MJ, Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol 2021;39:3328–3339.)| false
• Search Google Scholar
• Export Citation

Schroeder T, Wegener N, Lauseker M, et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transplant 2019;25:1550–1559.

• PubMed
Schroeder T, Wegener N, Lauseker M, Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transplant 2019;25:1550–1559.)| false
• Search Google Scholar
• Export Citation